commd7 Gene Expression in ALL

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05592470
Collaborator
(none)
102
24

Study Details

Study Description

Brief Summary

  • study the expression pattern of COMMD7 gene in acute lymphoblastic leukemia.

  • investigate correlation between the expression level of COMMD7 gene with other diagnostic parameters and prognosis in ALL .

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

Detailed Description

Acute lymphoblastic leukemia (ALL) is a neoplastic disorder of lymphoid progenitor cells characterized by diverse cytogenetic and molecular abnormalities with peaks of prevalence for 2-5-year-old patients and those older than 50. Treatment strategies using risk-adapted chemotherapy cure more than 80% of childhood cases, but around 20 to 30% relapse developing serious complications including death.( 1) In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes.(2) The copper metabolism MURR1 domain (COMMD) protein family involved in tumor development and progression in several types of human cancer, but little is known about the function of COMMD proteins in hematological malignancy. (3) COMMD7, a member of the COMMD, which is located on chromosome 20q11.21, has been reported associated with tumor progression in human solid cancers [4]. COMMD7 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) cells, associated with poor prognosis. [5]. Another study revealed that COMMD7-overexpressed hepatocellular carcinoma (HCC) cells promoted the proliferation of naïve HCC cells (6) A recent study was found that high expression of COMMD7 is a potential biomarker for adverse outcomes and poor prognosis in AML. (7)

. However, to date, the expression of COMMD7 in acute lymphoblastic leukemia and its prognostic value remain unclear.

Study Design

Study Type:
Observational
Anticipated Enrollment :
102 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
The Copper Metabolism MURR1 Domain 7 (COMMD7) Gene Expression in Acute Lymphoblastic Leukemia
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
PATEINTS

51 patients newly diagnosed with acute lymphoblastic leukemia

Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia

controls

51 normal persons

Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia

Outcome Measures

Primary Outcome Measures

  1. The expression pattern of COMMD7 gene in acute lymphoblastic leukemia [BASELINE]

    Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) TO DETECT EXPRESSION pattern in ALL

Secondary Outcome Measures

  1. Correlation between the expression level of COMMD7 GENE with other diagnostic parameters and prognosis in ALL [baseline]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients newly diagnosed with acute lymphoblastic leukemia , male or female at any age.
Exclusion Criteria:
  • history of anti-neoplastic therapy, such as chemotherapy or radiotherapy.

  • Any other types of cancers.

  • Any clinically systemic acute or chronic inflammatory disease/s within one months.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Marwa Saad Mohamed Mahrous, AssuitU, Assiut University
ClinicalTrials.gov Identifier:
NCT05592470
Other Study ID Numbers:
  • commd7 gene expression in ALL
First Posted:
Oct 24, 2022
Last Update Posted:
Oct 24, 2022
Last Verified:
Sep 1, 2022
Keywords provided by Marwa Saad Mohamed Mahrous, AssuitU, Assiut University

Study Results

No Results Posted as of Oct 24, 2022